Log in

NASDAQ:ADRO - Aduro BioTech Stock Price, Forecast & News

$2.95
-0.47 (-13.74 %)
(As of 02/28/2020 01:19 AM ET)
Today's Range
$2.94
Now: $2.95
$3.38
50-Day Range
$1.15
MA: $2.28
$3.87
52-Week Range
$0.90
Now: $2.95
$4.59
Volume1.51 million shs
Average Volume1.53 million shs
Market Capitalization$237.52 million
P/E RatioN/A
Dividend YieldN/A
Beta1.41
Aduro BioTech, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies to harness the body's natural immune system for the treatment of patients with challenging diseases. The company is developing ADU-S100, which is in Phase I dose escalation and dose expansion clinical trial and Phase Ib dose escalation and dose expansion clinical trial in combination with spartalizumab to treat patients with advanced, metastatic treatment-refractory solid tumors; Phase I clinical trial in combination with ipilimumab for the treatment of relapsed and refractory melanoma; and Phase Ib/II clinical trial in combination with an approved anti-PD-1 antibody in patients with squamous cell carcinoma of the head and neck. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ADRO
CUSIPN/A
Phone510-848-4400

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$15.09 million
Book Value$1.70 per share

Profitability

Net Income$-95,360,000.00
Net Margins-544.94%

Miscellaneous

Employees152
Market Cap$237.52 million
Next Earnings DateN/A
OptionableOptionable

Receive ADRO News and Ratings via Email

Sign-up to receive the latest news and ratings for ADRO and its competitors with MarketBeat's FREE daily newsletter.


Aduro BioTech (NASDAQ:ADRO) Frequently Asked Questions

What is Aduro BioTech's stock symbol?

Aduro BioTech trades on the NASDAQ under the ticker symbol "ADRO."

How were Aduro BioTech's earnings last quarter?

Aduro BioTech Inc (NASDAQ:ADRO) announced its quarterly earnings results on Thursday, November, 7th. The biotechnology company reported ($0.20) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.23) by $0.03. The biotechnology company had revenue of $4.80 million for the quarter, compared to analysts' expectations of $4.55 million. Aduro BioTech had a negative net margin of 544.94% and a negative return on equity of 78.64%. View Aduro BioTech's Earnings History.

What price target have analysts set for ADRO?

7 Wall Street analysts have issued 1 year price targets for Aduro BioTech's shares. Their forecasts range from $4.00 to $7.00. On average, they anticipate Aduro BioTech's share price to reach $5.50 in the next twelve months. This suggests a possible upside of 86.4% from the stock's current price. View Analyst Price Targets for Aduro BioTech.

What is the consensus analysts' recommendation for Aduro BioTech?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aduro BioTech in the last year. There are currently 4 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Aduro BioTech.

Has Aduro BioTech been receiving favorable news coverage?

Media coverage about ADRO stock has been trending very negative this week, InfoTrie Sentiment Analysis reports. The research group ranks the sentiment of news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Aduro BioTech earned a daily sentiment score of -3.2 on InfoTrie's scale. They also gave media headlines about the biotechnology company a news buzz of 4.0 out of 10, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next few days. View News Stories for Aduro BioTech.

Are investors shorting Aduro BioTech?

Aduro BioTech saw a increase in short interest during the month of February. As of February 14th, there was short interest totalling 2,440,000 shares, an increase of 24.5% from the January 30th total of 1,960,000 shares. Based on an average daily trading volume, of 1,200,000 shares, the days-to-cover ratio is currently 2.0 days. Currently, 4.8% of the shares of the stock are short sold. View Aduro BioTech's Current Options Chain.

Who are some of Aduro BioTech's key competitors?

What other stocks do shareholders of Aduro BioTech own?

Who are Aduro BioTech's key executives?

Aduro BioTech's management team includes the folowing people:
  • Mr. Stephen T. Isaacs, Chairman, CEO & Pres (Age 70)
  • Dr. Andrea van Elsas, Chief Scientific Officer (Age 52)
  • Mr. Blaine E. Templeman, Chief Admin. Officer & Chief Legal Officer (Age 53)
  • Ms. Jennifer Lew, Chief Financial Officer (Age 46)
  • Ms. Alexandra Santos, Exec. Director of Corp. Affairs & Investor Relations

When did Aduro BioTech IPO?

(ADRO) raised $119 million in an IPO on Wednesday, April 15th 2015. The company issued 7,000,000 shares at a price of $17.00 per share. BofA Merrill Lynch and Leerink Partners acted as the underwriters for the IPO and William Blair and Canaccord Genuity were co-managers.

Who are Aduro BioTech's major shareholders?

Aduro BioTech's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (5.76%), Baillie Gifford & Co. (5.26%), Ikarian Capital LLC (2.28%), State Street Corp (1.49%), Geode Capital Management LLC (1.08%) and Goldman Sachs Group Inc. (0.96%). Company insiders that own Aduro BioTech stock include Blaine Templeman, Celeste Ferber, Elsas Andrea Van, Jennifer Lew, Natalie Sacks and Stephen T Isaacs. View Institutional Ownership Trends for Aduro BioTech.

Which institutional investors are selling Aduro BioTech stock?

ADRO stock was sold by a variety of institutional investors in the last quarter, including Panagora Asset Management Inc., State Street Corp, Assenagon Asset Management S.A. and Bank of America Corp DE. Company insiders that have sold Aduro BioTech company stock in the last year include Blaine Templeman, Celeste Ferber, Elsas Andrea Van, Jennifer Lew and Stephen T Isaacs. View Insider Buying and Selling for Aduro BioTech.

Which institutional investors are buying Aduro BioTech stock?

ADRO stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Ikarian Capital LLC, Goldman Sachs Group Inc., Acadian Asset Management LLC, Jacobs Levy Equity Management Inc., J. Goldman & Co LP, Oxford Asset Management LLP and Connor Clark & Lunn Investment Management Ltd.. View Insider Buying and Selling for Aduro BioTech.

How do I buy shares of Aduro BioTech?

Shares of ADRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Aduro BioTech's stock price today?

One share of ADRO stock can currently be purchased for approximately $2.95.

How big of a company is Aduro BioTech?

Aduro BioTech has a market capitalization of $237.52 million and generates $15.09 million in revenue each year. The biotechnology company earns $-95,360,000.00 in net income (profit) each year or ($1.16) on an earnings per share basis. Aduro BioTech employs 152 workers across the globe.View Additional Information About Aduro BioTech.

What is Aduro BioTech's official website?

The official website for Aduro BioTech is http://www.aduro.com/.

How can I contact Aduro BioTech?

Aduro BioTech's mailing address is 740 HEINZ AVENUE, BERKELEY CA, 94710. The biotechnology company can be reached via phone at 510-848-4400 or via email at [email protected]


MarketBeat Community Rating for Aduro BioTech (NASDAQ ADRO)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  443 (Vote Outperform)
Underperform Votes:  260 (Vote Underperform)
Total Votes:  703
MarketBeat's community ratings are surveys of what our community members think about Aduro BioTech and other stocks. Vote "Outperform" if you believe ADRO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ADRO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel